1-15 of 15
Paolo Nuciforo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors

Anthony El-Khoueiry, Omar Saavedra, Jacob Thomas, Claire Livings, Elena Garralda, Gabriele Hintzen, Laura Kohlhas, Dessislava Vanosmael, Joachim Koch, Erich Rajkovic, Paulien Ravenstijn, Paolo Nuciforo, Todd A. Fehniger, Mark Foster, Melissa M. Berrien-Elliott, Susanne Wingert, Sina Stäble, Daniela Morales-Espinosa, Delcia Rivas, Michael Emig, Juanita Lopez
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF11.
https://doi.org/10.1158/1078-0432.CCR-24-1991
Published: 27 February 2025
View article titled, First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Open the PDF for First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma During Targeted Therapy

Alberto González-Medina, Maria Vila-Casadesús, Marina Gomez-Rey, Carles Fabregat-Franco, Alexandre Sierra, Tian V. Tian, Florian Castet, Gloria Castillo, Judit Matito, Paola Martinez, Josep M. Miquel, Paolo Nuciforo, Raquel Pérez-López, Teresa Macarulla, Ana Vivancos
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4491–4504.
https://doi.org/10.1158/1078-0432.CCR-23-3780
Published: 01 October 2024
View article titled, Clinical Value of Liquid Biopsy in Patients with <em>FGFR2</em> Fusion–Positive Cholangiocarcinoma During Targeted Therapy
Open the PDF for Clinical Value of Liquid Biopsy in Patients with <em>FGFR2</em> Fusion–Positive Cholangiocarcinoma During Targeted Therapy in another window
Includes: Supplementary data
Journal Articles

High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

Mònica Sánchez-Guixé, Cinta Hierro, José Jiménez, Cristina Viaplana, Guillermo Villacampa, Erika Monelli, Fara Brasó-Maristany, Zighereda Ogbah, Mireia Parés, Marta Guzmán, Judit Grueso, Olga Rodríguez, Mafalda Oliveira, Analía Azaro, Elena Garralda, Josep Tabernero, Oriol Casanovas, Maurizio Scaltriti, Aleix Prat, Rodrigo Dienstmann, Paolo Nuciforo, Cristina Saura, Mariona Graupera, Ana Vivancos, Jordi Rodon, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 137–149.
https://doi.org/10.1158/1078-0432.CCR-21-1810
Published: 05 January 2022
View article titled, High <em>FGFR1–4</em> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Open the PDF for High <em>FGFR1–4</em> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis

Sara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, Chiara Gargiuli, Loris De Cecco, Evandro de Azambuja, Debora Fumagalli, Christos Sotiriou, Nadia Harbeck, Miguel Izquierdo, Paolo Nuciforo, Jens Huober, Vera Cappelletti, Saverio Cinieri, Martine Piccart, Maria Grazia Daidone, Giancarlo Pruneri, Mario Paolo Colombo, Elda Tagliabue, Paolo Verderio, Serena Di Cosimo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6307–6313.
https://doi.org/10.1158/1078-0432.CCR-21-1600
Published: 01 December 2021
View article titled, Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Open the PDF for Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis in another window
Includes: Supplementary data
Journal Articles

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

Ioannis A. Vathiotis, Myrto K. Moutafi, Prajan Divakar, Thazin Nwe Aung, Tao Qing, Aileen Fernandez, Vesal Yaghoobi, Sarra El-Abed, Yingbo Wang, Sebastien Guillaume, Paolo Nuciforo, Jens Huober, Serena Di Cosimo, Sung-Bae Kim, Nadia Harbeck, Henry Gomez, Saba Shafi, Konstantinos N. Syrigos, George Fountzilas, Christos Sotiriou, Lajos Pusztai, Sarah Warren, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6156–6163.
https://doi.org/10.1158/1078-0432.CCR-21-2103
Published: 15 November 2021
View article titled, Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer
Open the PDF for Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

David Venet, Mattia Rediti, Marion Maetens, Debora Fumagalli, David N. Brown, Samira Majjaj, Roberto Salgado, Lajos Pusztai, Nadia Harbeck, Sarra El-Abed, Yingbo Wang, Cristina Saura, Henry Gomez, Vladimir Fedorovich Semiglazov, Evandro de Azambuja, Jens Huober, Paolo Nuciforo, Serena Di Cosimo, Martine Piccart, Sherene Loi, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5607–5618.
https://doi.org/10.1158/1078-0432.CCR-21-1317
Published: 15 October 2021
View article titled, Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
Open the PDF for Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

Eva Ciruelos, Patricia Villagrasa, Tomás Pascual, Mafalda Oliveira, Sonia Pernas, Laia Paré, Santiago Escrivá-de-Romaní, Luis Manso, Barbara Adamo, Eduardo Martínez, Javier Cortés, Silvia Vazquez, Antonia Perelló, Isabel Garau, Mireia Melé, Noelia Martínez, Alvaro Montaño, Begoña Bermejo, Serafin Morales, María J. Echarri, Estela Vega, Blanca González-Farré, Débora Martínez, Patricia Galván, Jordi Canes, Paolo Nuciforo, Xavier Gonzalez, Aleix Prat
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 5820–5829.
https://doi.org/10.1158/1078-0432.CCR-20-0844
Published: 13 November 2020
View article titled, Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
Open the PDF for Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial in another window
Includes: Supplementary data
Journal Articles

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Albert Gris-Oliver, Marta Palafox, Laia Monserrat, Fara Brasó-Maristany, Andreu Òdena, Mònica Sánchez-Guixé, Yasir H. Ibrahim, Guillermo Villacampa, Judit Grueso, Mireia Parés, Marta Guzmán, Olga Rodríguez, Alejandra Bruna, Caroline S. Hirst, Alan Barnicle, Elza C. de Bruin, Avinash Reddy, Gaia Schiavon, Joaquín Arribas, Gordon B. Mills, Carlos Caldas, Rodrigo Dienstmann, Aleix Prat, Paolo Nuciforo, Pedram Razavi, Maurizio Scaltriti, Nicholas C. Turner, Cristina Saura, Barry R. Davies, Mafalda Oliveira, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3720–3731.
https://doi.org/10.1158/1078-0432.CCR-19-3324
Published: 15 July 2020
View article titled, Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Open the PDF for Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts in another window
Includes: Supplementary data
Journal Articles

Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy

Carmine De Angelis, Chandandeep Nagi, Cliff C. Hoyt, Linying Liu, Kristin Roman, Chichung Wang, Yi Zheng, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Paolo Nuciforo, Tao Wang, Anna Tsimelzon, Sufeng Mao, Susan G. Hilsenbeck, Meghana V. Trivedi, Maria Letizia Cataldo, Anne Pavlick, Antonio C. Wolff, Britta Weigelt, Jorge S. Reis-Filho, Aleix Prat, Carolina Gutierrez, Charles Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (3): 738–745.
https://doi.org/10.1158/1078-0432.CCR-19-1402
Published: 03 February 2020
View article titled, Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy
Open the PDF for Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Abstract B02: Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers

Violeta Serra, Cristina Cruz, Marta Castroviejo, Sara Gutiérrez, Alba Llop, Alejandra Bruna, Beatriz Morancho, Ginevra Caratú, Ludmila Prudkin, Ana Vivancos, Paolo Nuciforo, Mark O'Connor, Jos Jonkers, Carlos Caldas, Joaquin Arribas, José Baselga, Isabel T. Rubio, Cristina Saura, Orland Díez, Judith Balmaña, Javier Cortés
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): B02.
https://doi.org/10.1158/1557-3265.PDX16-B02
Published: 15 August 2016
View article titled, Abstract B02: Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers
Journal Articles

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay

Aleix Prat, Patricia Galván, Begoña Jimenez, Wesley Buckingham, H. Arthur Jeiranian, Carl Schaper, Maria Vidal, Martina Álvarez, Sherley Díaz, Catherine Ellis, Paolo Nuciforo, Sean Ferree, Nuria Ribelles, Barbara Adamo, Santiago Ramón y Cajal, Vicente Peg, Emilio Alba
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (3): 560–566.
https://doi.org/10.1158/1078-0432.CCR-15-0630
Published: 31 January 2016
View article titled, Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
Open the PDF for Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay in another window
Includes: Supplementary data
Journal Articles

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

Oriol Arqués, Irene Chicote, Isabel Puig, Stephan P. Tenbaum, Guillem Argilés, Rodrigo Dienstmann, Natalia Fernández, Ginevra Caratù, Judit Matito, Daniel Silberschmidt, Jordi Rodon, Stefania Landolfi, Aleix Prat, Eloy Espín, Ramón Charco, Paolo Nuciforo, Ana Vivancos, Wenlin Shao, Josep Tabernero, Héctor G. Palmer
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 644–656.
https://doi.org/10.1158/1078-0432.CCR-14-3081
Published: 31 January 2016
View article titled, Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
Open the PDF for Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer

Celina García-García, Martín A. Rivas, Yasir H. Ibrahim, María Teresa Calvo, Albert Gris-Oliver, Olga Rodríguez, Judit Grueso, Pilar Antón, Marta Guzmán, Claudia Aura, Paolo Nuciforo, Katti Jessen, Guillem Argilés, Rodrigo Dienstmann, Andrea Bertotti, Livio Trusolino, Judit Matito, Ana Vivancos, Irene Chicote, Héctor G. Palmer, Josep Tabernero, Maurizio Scaltriti, José Baselga, Violeta Serra
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (24): 5499–5510.
https://doi.org/10.1158/1078-0432.CCR-14-3091
Published: 14 December 2015
View article titled, MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <em>TP53</em> Mutation in Preclinical Models of Colorectal Cancer
Open the PDF for MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <em>TP53</em> Mutation in Preclinical Models of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Howard M. Stern, Humphrey Gardner, Tomasz Burzykowski, Wafaa Elatre, Carol O'Brien, Mark R. Lackner, Gary A. Pestano, Angela Santiago, Ivonne Villalobos, Wolfgang Eiermann, Tadeusz Pienkowski, Miguel Martin, Nicholas Robert, John Crown, Paolo Nuciforo, Valerie Bee, John Mackey, Dennis J. Slamon, Michael F. Press
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (9): 2065–2074.
https://doi.org/10.1158/1078-0432.CCR-14-2993
Published: 30 April 2015
View article titled, PTEN Loss Is Associated with Worse Outcome in <em>HER2</em>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Open the PDF for PTEN Loss Is Associated with Worse Outcome in <em>HER2</em>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance in another window
Includes: Supplementary data
Journal Articles

High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab

Maurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, Jeff Sperinde, Dominique Agbor-Tarh, Christine Campbell, Ahmed Chenna, John Winslow, Violeta Serra, Josep Lluis Parra, Ludmila Prudkin, José Jimenez, Claudia Aura, Nadia Harbeck, Lajos Pusztai, Catherine Ellis, Holger Eidtmann, Joaquin Arribas, Javier Cortes, Evandro de Azambuja, Martine Piccart, José Baselga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (3): 569–576.
https://doi.org/10.1158/1078-0432.CCR-14-1824
Published: 01 February 2015
View article titled, High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Open the PDF for High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab in another window
Includes: Supplementary data